$WVE
Wave Life Sciences Ltd.

2021 Q1 Form 10-Q Financial Statement

#000156459021027223 Filed on May 13, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $0.00 $4.160M
YoY Change -100.0% 37.48%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.08M $13.00M
YoY Change -22.46% 19.27%
% of Gross Profit
Research & Development $33.39M $41.16M
YoY Change -18.87% 2.61%
% of Gross Profit
Depreciation & Amortization $1.948M $2.039M
YoY Change -4.46% 14.36%
% of Gross Profit
Operating Expenses $43.47M $54.15M
YoY Change -19.73% 6.16%
Operating Profit -$43.47M -$49.99M
YoY Change -13.05% 4.18%
Interest Expense $10.00K $390.0K
YoY Change -97.44% -72.54%
% of Operating Profit
Other Income/Expense, Net $1.007M $2.120M
YoY Change -52.5% -44.03%
Pretax Income -$42.46M -$47.49M
YoY Change -10.58% 7.44%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$42.46M -$47.49M
YoY Change -10.59% 7.45%
Net Earnings / Revenue -1141.66%
Basic Earnings Per Share
Diluted Earnings Per Share -$864.8K -$1.378M
COMMON SHARES
Basic Shares Outstanding 49.00M 34.54M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $148.5M $120.9M
YoY Change 22.83% -57.96%
Cash & Equivalents $148.5M $120.9M
Short-Term Investments
Other Short-Term Assets $16.00M $18.84M
YoY Change -15.09% 7.67%
Inventory
Prepaid Expenses $9.999M
Receivables $30.00M $0.00
Other Receivables $0.00 $18.70M
Total Short-Term Assets $194.5M $149.8M
YoY Change 29.84% -52.44%
LONG-TERM ASSETS
Property, Plant & Equipment $43.10M $52.60M
YoY Change -18.06% -11.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.000M $6.100M
YoY Change -18.03% -3.17%
Total Long-Term Assets $48.10M $88.80M
YoY Change -45.83% -23.18%
TOTAL ASSETS
Total Short-Term Assets $194.5M $149.8M
Total Long-Term Assets $48.10M $88.80M
Total Assets $242.6M $238.6M
YoY Change 1.68% -44.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.40M $16.50M
YoY Change -18.79% 13.01%
Accrued Expenses $10.50M $14.40M
YoY Change -27.08% 26.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $48.70M $118.9M
YoY Change -59.04% -9.84%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $133.3M $91.00M
YoY Change 46.48% -3.19%
Total Long-Term Liabilities $133.3M $91.00M
YoY Change 46.48% -3.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $48.70M $118.9M
Total Long-Term Liabilities $133.3M $91.00M
Total Liabilities $182.0M $209.8M
YoY Change -13.25% -7.13%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $52.82M $20.86M
YoY Change
Total Liabilities & Shareholders Equity $242.6M $238.6M
YoY Change 1.68% -44.59%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$42.46M -$47.49M
YoY Change -10.59% 7.45%
Depreciation, Depletion And Amortization $1.948M $2.039M
YoY Change -4.46% 14.36%
Cash From Operating Activities -$44.38M -$26.25M
YoY Change 69.05% -47.9%
INVESTING ACTIVITIES
Capital Expenditures $108.0K $580.0K
YoY Change -81.38% 14.17%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$108.0K -$580.0K
YoY Change -81.38% 14.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.641M 614.0K
YoY Change 1307.33% -99.62%
NET CHANGE
Cash From Operating Activities -44.38M -26.25M
Cash From Investing Activities -108.0K -580.0K
Cash From Financing Activities 8.641M 614.0K
Net Change In Cash -35.96M -26.21M
YoY Change 37.21% -123.25%
FREE CASH FLOW
Cash From Operating Activities -$44.38M -$26.25M
Capital Expenditures $108.0K $580.0K
Free Cash Flow -$44.48M -$26.83M
YoY Change 65.8% -47.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
388000
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49101606
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34461505
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-120000
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42584000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47487000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
63732000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33393000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10078000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
43471000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-43471000
CY2021Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
11000
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
3999000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
20858000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
82778000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
4063000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
200000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
336000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-120000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41158000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12996000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
54154000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-49993000
CY2020Q1 wve Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
442000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-47493000
CY2021Q1 wve Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
512000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-42464000
CY2021Q1 us-gaap Depreciation
Depreciation
1948000
CY2020Q1 us-gaap Depreciation
Depreciation
2039000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4063000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3999000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-20000000
CY2021Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-4000
CY2020Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
373000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1715000
CY2020Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1983000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-466000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7336000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-5310000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-5191000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4161000
CY2020Q1 wve Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-765000
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-100000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26250000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
580000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-580000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8641000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
614000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-120000
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-35962000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26210000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
188148000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
150808000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
152186000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
124598000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-42464000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
52821000
CY2021Q1 wve Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-880000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-67000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
108000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44375000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-108000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
200000
CY2021Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
336000
CY2021Q1 wve At Market Offering Costs In Accounts Payable
AtMarketOfferingCostsInAccountsPayable
77000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
148500000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0001564590-21-027223-index-headers.html Edgar Link pending
0001564590-21-027223-index.html Edgar Link pending
0001564590-21-027223.txt Edgar Link pending
0001564590-21-027223-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
guhsvx4e3cx1000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
wve-10q_20210331.htm Edgar Link pending
wve-10q_20210331_htm.xml Edgar Link completed
wve-20210331.xsd Edgar Link pending
wve-20210331_cal.xml Edgar Link unprocessable
wve-20210331_def.xml Edgar Link unprocessable
wve-20210331_lab.xml Edgar Link unprocessable
wve-20210331_pre.xml Edgar Link unprocessable
wve-ex102_80.htm Edgar Link pending
wve-ex103_79.htm Edgar Link pending
wve-ex311_7.htm Edgar Link pending
wve-ex312_8.htm Edgar Link pending
wve-ex32_6.htm Edgar Link pending